title: [Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy].
abstract: The purpose of the study was to identify breast cancer subtypes by immunohistochemistry likely to respond to neoadjuvant chemotherapy and to analyze the used chemotherapy regimen and the range of response rates. Analysis of a collected database was performed. Ninety-two patients were identified in our files who received neoadjuvant chemotherapy between 1998 and 2009. We used immunohistochemical profiles (ER, PgR, HER2, Ki-67 and p53) of NCB, FNAB and surgical breast specimens to subclassify the tumors. Pathological response rates were assessed following surgical removal of tumors by using the Chevallier classification. DFS and OS was measured in 88 cases from the date of definitive surgery to the date of last follow-up or death. Pathological complete or near-complete remission (pCR = Chevallier I and II) was observed in 13 of 92 cases (14.1%). According to the preoperative characteristics of the 13 tumors achieving pCR, 9 of the cases were triple negative, one of 13 was ER-/HER2+ and three of 13 ER+/HER2+. Twenty-four of 92 patients received taxane based neoadjuvant chemotherapy, 30 of 92 anthracycline based neoadjuvant chemotherapy, 33 of 92 taxane + anthracycline regimen and 2 of 92 CMF regimen. In the taxane treated group of patients the pCR rate was 29.1%, in the anthracycline group 6.6% and in the taxane + anthracycline treated group 12.1%. Concerning DFS, significant difference was observed between the Chevallier III and IV groups (p=0.006), and less events were observed in the pCR group (not significant). pCR was associated with significantly better OS (p=0.050). It seems that even limited, routinely used immunohistochemical profiling of tumors is able to predict the likelihood of pCR to neoadjuvant chemotherapy. Patients with triple negative and HER2-positive cancers are likely to achieve pCR after neoadjuvant chemotherapy.
authors.affiliation: Semmelweis Egyetem II. sz. Patológiai Intézet 1091 Budapest Ulloi út 93. kj@korb2.sote.hu
authors.forename: Janina
authors.initials: J
authors.lastname: Kulka
authors.forename: Anna-Mária
authors.initials: AM
authors.lastname: Tokés
authors.forename: Adrienn Ildikó
authors.initials: AI
authors.lastname: Tóth
authors.forename: Attila Marcell
authors.initials: AM
authors.lastname: Szász
authors.forename: Andrea
authors.initials: A
authors.lastname: Farkas
authors.forename: Katalin
authors.initials: K
authors.lastname: Borka
authors.forename: Balázs
authors.initials: B
authors.lastname: Járay
authors.forename: Eszter
authors.initials: E
authors.lastname: Székely
authors.forename: Roland
authors.initials: R
authors.lastname: Istók
authors.forename: Gábor
authors.initials: G
authors.lastname: Lotz
authors.forename: Lilla
authors.initials: L
authors.lastname: Madaras
authors.forename: Anna
authors.initials: A
authors.lastname: Korompay
authors.forename: László
authors.initials: L
authors.lastname: Harsányi
authors.forename: Zsolt
authors.initials: Z
authors.lastname: László
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Rusz
authors.forename: Béla Akos
authors.initials: BA
authors.lastname: Molnár
authors.forename: István Arthur
authors.initials: IA
authors.lastname: Molnár
authors.forename: István
authors.initials: I
authors.lastname: Kenessey
authors.forename: Gyöngyvér
authors.initials: G
authors.lastname: Szentmártoni
authors.forename: Borbála
authors.initials: B
authors.lastname: Székely
authors.forename: Magdolna
authors.initials: M
authors.lastname: Dank
mesh_terms: D018943:Anthracyclines / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000032:analysis; D020360:Neoadjuvant Therapy / Q000379:methods*; D010641:Phenotype; D011237:Predictive Value of Tests; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000032:analysis
chemical_list: D018943:Anthracyclines; D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D043823:Taxoids; D016159:Tumor Suppressor Protein p53; C508053:ERBB2 protein, human